Compare OBE & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBE | ALLO |
|---|---|---|
| Founded | 1979 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.9M | 539.4M |
| IPO Year | 2005 | 2018 |
| Metric | OBE | ALLO |
|---|---|---|
| Price | $9.74 | $2.60 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $10.00 | $8.40 |
| AVG Volume (30 Days) | 907.9K | ★ 4.6M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.21 | $144,130.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.88 | $0.86 |
| 52 Week High | $9.81 | $2.80 |
| Indicator | OBE | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 70.50 | 57.21 |
| Support Level | $5.57 | $2.14 |
| Resistance Level | N/A | $2.71 |
| Average True Range (ATR) | 0.40 | 0.22 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 98.34 | 80.31 |
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Sale of Oil.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.